CD28/B7 costimulation: A review

Critical Reviews in Immunology

Volumn 18, Issue 5, 1998, Pages 389-418

  Greenfield, Edward A ^a,b   Nguyen, Kuong A ^a   Kuchroo, Vijay K ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

B7; CD28; Costimulation; CTLA4

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BINDING AFFINITY; CYTOKINE RELEASE; DIABETES MELLITUS; DOWN REGULATION; GRAFT REJECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0031671268     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v18.i5.10     Document Type: Review

References (229)

1. Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., and Damle, N. K., Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes, J. Exp. Med., 176,1595-1604, 1992.
2. June, C. H., Bluestone, J. A., Nadler, L. M., and Thompson, C. B., The B7 and CD28 receptor families, Immunol. Today, 15, 321-331, 1994.
3. Gross, J. A., St. John, T., and Allison, J. P., The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression, J. Immunol., 144, 3201-3210, 1990.
4. Truneh, A., Reddy, M., Ryan, P., Lyn, S.-D., Eichman, C., Couez, D., Hurle, M. R., Sekaly, R. P., Olive, D., and Sweet, R., Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis, Mol. Immunol., 33, 321-334, 1996.
5. Cerdan, C., Martin, Y., Courcoul, M., Brailly, H., Mawas, C., Birg, F., and Olive, D., Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and posttranscriptional regulation, J. Immunol. 149, 2255-2261, 1992.
6. Freeman, G. J., Boussiotis, V. A., Anumanthan, A., Bernstein, G. M., Ke, X. Y., Rennert, P. D., Gray, G. S., Gribben, J. G., and Nadler, L. M., B7-1 and B7-2 do not deliver identical costimulatory signals, as B7-2 but not B7-1 preferentially costimulates the initial production of IL4, Immunity, 2, 523-532, 1995.
7. Fraser, J. D. and Weiss A., Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28, Mol. Cell. Biol. 12, 4357-4363, 1992.
8. Thompson, C. B., Lindsten, T., Ledbetter, J. A., Kunkel, S. L., Young, H. A., Emerson, S. G., Leiden, J. M., and June, C. H., CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines, Proc. Natl. Acad. Sci. U.S.A., 86, 1333-1337, 1989.
9. Mueller, D. L., Jenkins, M. K., and Schwartz, R. H., Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy, Annu. Rev. Immunol. 7, 445-480, 1989.
10. Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., and Ledbetter, J. A., Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation, J. Exp. Med., 173, 721-730, 1991.
11. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Sugita, K., Freedman, A. S., Morimoto, C., and Nadler, L. M., B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin-2, Proc. Natl. Acad. Sci. U.S.A., 88, 6575-6579, 1991.
12. Lindsten, T., Lee, K. P., Harris, E. S., Petryniak, B., Craighead, N., Reynolds, P. J., Lonibard, D. B., Freeman, G. J., Nadler, L. M., Gray, G. S., et al., Characterization of CTLA-4 structure and expression on human T cells, J. lmmunol., 151, 3489-3499, 1993.
13. de Boer, M., Kasran, A., Kwekkeboom, J., Walter, H., Vandenberghe, P., and Ceuppens, J. L., Ligation of B7 with CD28/CTLA-4 on T cells results inCD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells, Eur. J. Immunol., 23, 3120-3125, 1993.
14. Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., and Thompson, C. B., CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL, Immunity, 3, 87-98, 1995.
15. August, A., Gibson, S., Kawakami, Y., Kawakami, T., Mills, G. B., and Dupont, B., CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/ EMT in the human Jurkat leukemic T-cell line, Proc. Natl. Acad. Sci. U.S.A., 91, 9347-9351, 1994.
16. Raab, M., Cai, Y. C., Bunnell, S. C., Heyeck, S. D., Berg, L. J., Rudd, C. E., pS6Lck and pS9Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation, Proc. Natl. Acad. Sci. U.S.A., 92, 8891-8895, 1995.
17. August, A. and Dupont, B., CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase, Int. Immunol., 6, 769-774, 1994.
18. Prasad, K. V., Cai, Y. C., Ranb, M., Duckworth, B., Cantley, L., Shoelson, S. E., and Rudd, C. E., T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-MetXaa-Met motif, Proc. Natl. Acad. Sci. U.S.A., 91, 2834-2838, 1994.
19. Truitt, K. E., Hicks, C. M., and Imboden, J. B., Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells, J. Exp. Med., 179, 1071-1076, 1994.
20. Brunet, J. F., Denizot, F., Luciani, M. F., Roux-Dosseto, M., Suzan, M., Mattei, M.G., and Golstein, P., A new member of the immunoglobulin superfamily-CTLA-4, Nature, 328, 267-270, 1987.
21. Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., and Ledbetter, J. A., CTLA-4 is a . second receptor for the B cell activation antigen B7, J. Exp. Med., 174, 561-569, 1991.
22. Schultze, J., Nadler, L. M., and Gribben, J. G., B7-mediated costimulation and the immune response, Blood Rev., 10, 111-127, 1996.
23. Harper, K., Balzano, C., Rouvier, E., Mattei, M. G., Luciani, M. F., and Golstein, P., CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location, J. Immunol., 147, 1037-1044, 1991.
24. Linsley, P. S., Nadler, S. G., Bajorath, J., Peach, R., Leung, H. T., Rogers, J., Bradshaw, J., Stebbins, M., Leytze, G., Brady, W., et al., Binding stoichiometry of the cytotoxic T lymphocyte associated molecule-4 (CTLA-4). A disulfide-linked hompdimer binds two CD86 molecules, J. Biol. Chem., 270, 15417-15424, 1995.
25. Ward S. G., CD28: a signaling perspective, Biochem. J., 318, 361-377, 1996.
26. Schneider, H., Prasad, K. V., Shoelson, S. E., and Rudd, C. E., CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells, J. Exp. Med., 181, 351-355, 1995.
27. Leung, H. T., Bradshaw, J., Cleaveland, J. S., and Linsley, P. S., Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail, J. Biol Chem., 270, 25107-25114, 1995.
28. Freeman, G. J., Lombard, D. B., Gimmi, C. D., Brod, S. A., Lee, K., Laning, J. C., Hafler, D. A., Dorf, M. E., Gray, G. S., Reiser, H., et al., CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production, J. Immunol., 149, 3795-3801, 1992.
29. Leach, D. R., Krummel, M. F., and Allison, J. P., Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734-1736, 1996.
30. Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L., and Mittler, R. S., Intracellular trafficking of CTLA-4 and focal localization toward sites of TCR engagement, Immunity, 4, 535-543, 1996.
31. Alegre, M. L., Noel, P. J., Eisfelder, B. J., Chuang, E., Clark, M. R., Reiner, S. L., and Thompson, C. B., Regulation of surface and intracellular expression of CTLA4 on mouse T cells, J. Immunol., 157, 4762-4770, 1996.
32. Stein, P. H., Fraser, J. D., and Weiss, A., The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase, Mol. Cell. Biol., 14, 3392-3402, 1994.
33. Krummel, M. F., Sullivan, T. J., and Allison, J. P., Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo, Int. Immunol., 8, 519-523, 1996.
34. Gribben, J. G., Freeman, G. J., Boussiotis, V. A., Rennert, P., Jellis, C. L., Greenfield, E., Barber, M., Restivo, V. A., Jr., Ke, X., Gray, G. S., et al., CTLA4 mediates antigen-specific apoptosis of human T cells, Proc. Natl. Acad. Sci. U.S.A., 92, 811-815, 1995.
35. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. A., CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405-413, 1994.
36. Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., and Sharpe, A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541-547, 1995.
37. Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., and Mak, T. W., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985-988, 1995.
38. Fargeas, C. A., Truneh, A., Reddy, M., Hurle, M., Sweet, R., Sekaly, R. P., Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4, J. Exp. Med., 182, 667-675, 1995.
39. Rennert, P., Furlong, K., Jellis, C., Greenfleld, E., Freeman, G. J., Ueda, Y., Levine, B., June, C. H., and Gray, G. S., The IgV domain of human B7-2 (CD86) is sufficient to costimulate T lymphocytes and induce cytokine secretion, Int. Immunol., 9, 805-813, 1997.
40. Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K., Laszlo, G., et al., Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production, J. Exp. Med., 178, 2185-2192, 1993.
41. Doty, R. T. and Clark, E. A., Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation, J. Immunol., 157, 3270-3279, 1996.
42. Boussiotis, V. A., Gribben, J. G., Freeman, G. J., and Nadler, L. M., Blockade of the CD28 costimulatory pathway: a means to induce tolerance, Curr. Opin. Immunol., 6, 797-807, 1994.
43. Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Jr., Lombard, L. A., Gray, G. S., and Nadler, L. M., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments], Science, 262, 909-911, 1993.
44. 4. Allison, J. P., CD28-B7 interactions in T-cell activation, Curr. Opin. Immunol., 6, 414-419, 1994.
45. Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., and Somoza, C., B70 antigen is a second ligand for CTLA-4 and CD28, Nature, 366, 76-79, 1993 .
46. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., and Nadler, L. M., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood, 84, 3261-3282, 1994.
47. Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., and Peach, R., Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [published erratum appears in Immunity, 1995, Feb. 2(2): following 203], Immunity, 1, 793-801, 1994.
48. Wechsler, A. S., Gordon, M. C., Dendorfer, U., and LeClair, K. P., Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway, J. Immunol., 153, 2515-2523, 1994.
49. van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., and Davis, S. J., CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics, J. Exp. Med., 185, 393-403, 1997.
50. Peach, R. J., Bajorath, J., Naemura, J., Leytze, G., Greene, J., Aruffo, A., and Linsley, P. S., Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28, J. Biol. Chem., 270, 21181-21187, 1995.
51. Caux, C., Vanbervliet, B., Massacrier, C., Azuma, M., Okumura, K., Lanier, L. L., and Banchereau, J., B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells, J. Exp. Med., 180, 1841-1847, 1994.
52. Engel, P., Gribben, J. G., Freeman, G. J., Zhou, L. J., Nozawa, Y., Abe, M., Nadler, L. M., Wakasa, H., and Tedder, T. F., The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen, Blood, 84, 1402-1407, 1994.
53. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P., and Modes, R. J., Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function, J. Exp. Med., 180, 631-640, 1994.
54. Hathcock, K. S., Laszlo, G., Dickler, H. B., Bradshaw, J., Linsley, P., and Hodes, R. J., Identification of an alternative CTLA-4 ligand costimulatory .for T cell activation [see comments], Science, 262, 905-907, 1993.
55. Boussiotis, V. A., Freeman, G. J., Gribben, J. G., Daley, J., Gray, G., and Nadler, L. M., Activated human B lymphocytes express three CTLA-4 counterreceptors that co stimulate T-cell activation, Proc. Natl. Acad. Sci. U.S.A., 90, 11059-11063, 1993.
56. Lenschow, D. J., Su, G. H., Zuckerman, L. A., Nabavi, N., Jellis, C. L., Gray, G. S., Miller, J., and Bluestone, J. A., Expression and functional significance of an additional ligand for CTLA-4, Proc. Natl. Acad. Sci. U.S.A., 90, 11054-11058, 1993.
57. Lenschow, D. J., Sperling, A. I., Cooke, M. P., Freeman, G., Rhee, L., Decker, D. C., Gray, G., Nadler, L. M., Goodnow, C. C., and Bluestone J. A., Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen, J. Immunol., 153, 1990-1997, 1994.
58. Prabhu Das, M. R., Zamvil, S. S., Bordello, F., Weiner, H. L., Sharpe, A. H., and Kuchroo, V. K., Reciprocal expression of costimulatory molecules, B7-1 and B7-2, on murine T cells following activation, Eur. J. Immunol., 25, 207-211, 1995.
59. Hart, D. N., Starling, G. C., Calder, V. L., and Fernando, N. S., B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation, Immunology, 79, 616-620, 1993.
60. Azuma, M., Yssel, H., Phillips, J. H., Spits, H., and Lanier, L. L., Functional expression of B7/BB 1 on activated T lymphocytes, J. Exp. Med., 177, 845-850, 1993.
61. Sansom, D. M. and Hall, N. D., B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro, Eur. J. Immunol., 23:295-298, 1993.
62. Borriello, F., Oliveros, J., Freeman, G. J., Nadler, L. M., and Sharpe, A. H., Differential expression of alternate mB7-2 transcripts, J. Immunol., 155, 5490-5497, 1995.
63. Willems, F., Marchant, A., Delville, J. P., Gerard, C., Delvaux, A., Velu, T., de Boer, M., and Goldman, M., Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes, Eur. J. Immunol., 24, 1007-1009, 1994.
64. Jenkins, M. K., The ups and downs of T cell costimulation, Immunity, 1, 443-446, 1994.
65. Borriello, F., Sethna, M. P., Boyd, S. D., Schweitzer, A. N., Tivol, E. A., Jacoby, D., Strom, T. B., Simpson, E. M., Freeman, G. J., and Sharpe, A. H., B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation, Immunity, 6, 303-313, 1997.
66. Han, S., Hathcock, K., Zheng, B., Kepler, T. B., Hodes, R., and Kelsoe, G., Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers, J. Immunol., 155, 556-567, 1995.
67. Freedman, A. S., Freeman, G. J., Rhynhart, K., and Nadler, L. M., Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway, Cell Immunol., 137, 429-437, 1991.
68. Cayeux, S., Richter, G., Noffz, G., Dorken, B., and Blankenstein, T., Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation, J. Immunol., 158, 2834-2841, 1997.
69. Cayeux, S., Beck, C., Aicher, A., Dorken, B., and Blankenstein, T., Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines, Eur. J. Immunol., 25, 2325-2331, 1995.
70. Yssel, H., Schneider, P. V., and Lanier, L. L., Interleukin-7 specifically induces the B7/BB 1 antigen on human cord blood and peripheral blood T cells and T cell clones, Int. Immunol., 5, 753-759, 1993.
71. Ding, L., Linsley, P. S., Huang, L. Y., Germain, R. N., and Shevach, E. M., IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression, J. Immunol., 151, 1224-1234, 1993.
72. Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., and Nickoloff, B. J., Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression, J. Immunol., 154, 2668-2677, 1995.
73. Kawamura, T. and Furue, M., Comparative analysis of B7-1 and B7-2 expression in Langearhans cells; differeiitial regulatlon by T helper type 1 and T helper-type 2 cytokines, Eur. J. Immunol., 25, 1913-1917, 1995.
74. Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M.G., Linsley, P. S., and Bluestone, J. A., Long-term survival of xeno-geneic pancreatic islet grafts induced by CTLA4lg. Science, 257, 789-792, 1992.
75. Guo, Y., Wu, Y., Zhao, M., Kong, X. P., and Liu, Y., Mutational analysts and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain, J. Exp. Med., 181, 1345-1355, 1995.
76. Inobe, M., Aoki, N., Linsley, P. S., Ledbetter, J. A., Abe, R., Murakami, M., and Uede, T., The role of the B7-la molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation, J. Immunol., 157, 582-588, 1996.
77. Nickoloff, B. J., Mitra, R. S., Lee, K., Turka, L. A., Green, J., Thompson, C., and Shimizu, Y., Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo, Am. J. Pathol., 142, 1029-1040, 1993.
78. Kuchroo, V. K., Martin, C. A., Greer, J. M., Ju, S. T., Sobel, R. A., and Dorf, M. E., Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis, J. Immunol., 151, 4371-4382, 1993.
79. Simon, A. K., Seipelt, E., and Sieper, J., Divergent T-cell cytokine patterns in inflammatory arthritis, Proc. Natl. Acad. Sci. U.S.A., 91, 8562-8566, 1994.
80. Mosmann, T. R. and Coffman, R. L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 7, 145-173, 1989.
81. Powrie, F. and Coffman, R. L., Cytokine regulation of T-cell function: potential for therapeutic intervention, Immunol. Today, 14, 270-274, 1993.
82. Thompson, C. B., Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell, 81, 979-982, 1995.
83. Lenschow, D. J., Herold, K. C., Rhee, L., Patel, B., Koons, A., Qin, H. Y., Fuchs, E., Singh, B., Thompson, G. B., and Bluestone, J. A., CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes, Immunity, 5, 285-293, 1996.
84. King, C. L., Xianli, J., June, C. H., Abe, R., and Lee, K. P., CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection, Eur. J. Immunol., 26, 2448-2455, 1996.
85. Brown, D. R., Green, J. M., Moskowitz, N. H., Davis, M., Thompson, C. B., and Reiner, S. L., Limited role of CD28-mediated signals in T helper subset differentiation, J. Exp. Med., 184, 803-810, 1996.
86. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., and Glimcher. L. H., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: application to autoimmune disease therapy, Cell, 80, 707-718, 1995.
87. Petro, T. M., Chen, S. S., and Panther, R. B., Effect of CD80 and CD86 on T cell cytokine production, Immunol. Invest., 24, 965-976, 1995.
88. Natesan, M., Razi-Wolf, Z., and Reiser, H., Costimulation of IL-4 production by murine B7-1 and B7-2 molecules, J. Immunol., 156, 2783-2791, 1996.
89. Lanier, L. L., O'Fallon, S., Somoza, C, Phillips, J. H., Linsley, P. S., Okumura, K., Ito, D., and Azuma, M., GD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol., 154, 97-105, 1995.
90. Ranger, A. M., Das, M. P., Kuchroo, V. K., and Glimcher, L. H., B7-2 (CD86) is essential for the development of IL-4-producing T cells, Int. Immunol., 8, 1549-1560, 1996.
91. Racke, M. K., Scott, D. E., QuIgley, L., Gray, G. S., Abe, R., June, C. H., and Perrin, P. J., Distinct roles for B7-1 (CD-80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis, J. Clin. Invest., 96, 2195-2203, 1995.
92. Perrin, P. J., Scott, D., Davis, T. A., Gray, G. S., Doggett, M. J., Abe, R., June, C. H., and Racke, M. K., Opposing effects of CTLA4-Ig and antiCD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis, J. Neuroimmunol., 65, 31-39, 1996.
93. Miller, S. D., Vanderlugt, C. L., Lenschow, D. J., Pope, J. G., Karandikar, N. J., Dal Canto, M. C., and Bluestone, J. A., Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE, Immunity, 3, 739-745, 1995.
94. Brown, J. A., Titus, R.G., Nabavi, N., and Glimcher, L. H., Blockade of CD86 ameliorates Leishmania major infection by downregulating the Th2 response, J. Infect. Dis., 174, 1303-1308, 1996.
95. Schweitzer, A. N., Borriello. F., Wong, R. C., Abbas, A. K., and Sharpe, A. H., Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86, J. Immunol., 158, 2713-2722, 1997.
96. Murphy, M. L., Engwerda, C. R., Gorak, P. M. A., and Kaye, P. M., B7-2 blockade enhances T cell responses to Leishmania donovani, J. Immunol., 159, 4460-4466, 1997.
97. Pearson, C. I., van Ewijk, W., and McDevitt, H. O., Induction of apoptotic and T helper 2:(Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice, J. Exp. Med., 185, 583-599, 1997.
98. Subramanian, G., Kazura, J. W., Pearlman, E., Jia, X., Malhotra, L, and King, C. L., B7-2 requirement for helminth-induced granuloma formation and CD4 type 2 T helper cell cytokine expression, J. Immunol., 158, 5914-5920, 1997.
99. Tsuyuki, S., Tsuyuki, J., Einsle, K., Kopf, M., and Coyle, A. J., Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response .and altered airway responsiveness, J. Exp. Med., 185, 1671-1679, 1997.
100. + Th2 cells for contact hypersensitivity, J. Immunol., 159, 4217-4226, 1997.
101. Corry, D. B., Reiner, S. L., Llnsley, P. S., and Locksley, R. M., Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis, J. Immunol.,153, 4142-4148, 1994.
102. Sayegh, M. H., Akalin, E., Hancock, W. W., Russell, M. E., Carpenter, C. B., Linsley, P. S., and Turka, L. A., CD28-B7 blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2, J. Exp. Med., 181, 1869-1874, 1995.
103. Chen, C., Faherty, D. A., Gault, A., Connaughton, S. E., Powers, G. D., Godfrey, D. I., and Nabavi, N., Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes, J. Immunol., 152, 2105-2114, 1994.
104. Wu, Y., Guo, Y., and Liu, Y., A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7, J. Exp. Med., 178, 1789-1793, 1993.
105. Kearney, E. R., Pape, K. A., Loh, D. Y., and Jenkins, M. K., Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo, Immunity, 1, 327-339, 1994.
106. + T cells, Eur. J. Immunol., 27, 598-608, 1997.
107. Minty, A., Chalon, P., Derocq, J. M., Dumont, X., Guillemot, J. C., Kaghad, M., Labit, C., Leplatois, P., Lianzun, P., Miloux, B., et al., Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses, Nature, 362, 248-250, 1993.
108. Seder, R. A., Germain, R. N., Linsley, P. S., and Paul, W. E., CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production, J. Exp. Med., 1994; 179, 299-304.
109. Cerdan, C., Martin, Y., Courcoul, M., Mawas, C., Birg, F., and Olive, D., CD28 costimulation up-regulates long-term IL-2R beta expression in human T cells through combined transcriptional and posttranscriptional regulation, J. Immunol., 154, 1007-1013, 1995.
110. Ding, L., Green, J. M., Thompson, C. B., and Shevach, E. M., B7/CD28-dependent and -independent induction of CD40 ligand expression, J. Immunol., 155, 5124-5132, 1995.
111. Fraser, J. D., Straus, D., and Weiss, A., Signal transduction events leading to T-cell lymphokine gene expression, Immunol. Today, 14, 357-362, 1993.
112. Nelson, P.J., Kim, H.T.,Manning, W.C.,Goralski, T. J., and Krensky, A. M., Genomic organization and transcriptional regulation of the RANTES chemokine gene, J. Immunol., 151, 2601-2612, 1993.
113. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G., and Nadler, L. M., Human T-cell clonal energy is induced by antigen presentation in the absence of B7 costimulation, Proc. Natl. Acad. Sci. U.S.A., 90, 6586-6590, 1993.
114. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., and Allison, J. P., CD28-mediated signaling costimulates murine T cells and prevents induction of energy in T-cell clones, Nature, 356, 607-609, 1992.
115. Jenkins, M. K., Ashwell, J. D., and Schwartz, R. H., Allogeneic non-T-spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells, J. Immunol., 1988; 140, 3324-3330,.
116. Quill, H. and Schwartz, R. H., Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness, J. Immunol., 138, 3704-3712, 1987.
117. + thymocytes, J. Immunol., 149, 3217-3224, 1992.
118. Jenkins, M. K. and Schwartz, R. H., Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo, J. Exp. Med., 165, 302-319, 1987.
119. Boussiotis, V. A., Freeman, G. J., Gray, G., Gribben, J., and Nadler, L. M., B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance, J. Exp. Med., 178, 1753-1763, 1993.
120. Boussiotis, V. A., Freeman, G. J., Grifffn, J. D., Gray, G. S., Gribben, J. G., Nadler, L. M., CD2 is involved in maintenance and reversal of human alloantigen-specific clonal energy, J. Exp. Med., 180, 1665-1673, 1994.
121. Jenkins, M. K., The role of cell division in the induction of clonal energy, Immunol. Today, 13, 69-73, 1992.
122. Beveriy, B., Kang, S.M., Lenardo, M. J., and Schwartz, R. H., Reversal of in vitro T cell clonal energy by IL-2 stimulation, Int. Immunol., 4, 661-671, 1992.
123. Essery, G., Feldmann, M., and Lamb, J. R., Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes, Immunology, 64, 413-417, 1988.
124. Kang, S. M., Beverly, B., Tran, A. C., Brorson, K., Schwartz, R. H., and Lenardo, M. J., Transactivation by AP-1 is a molecular target of T cell clonal energy, Science, 257, 1134-1138, 1992.
125. Mondino, A. and Jenkins, M. K., Surface proteins involved in T cell costimulation, J. Leuloc. Biol., 55, 805-815, 1994.
126. Schorle, H., Holtschke, T., Hunig, T., Schimpl, A., and Horak, I., Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting, Nature, 352, 621-624, 1991.
127. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeharh, A., Kawai, K., Ohashi, P. S., Thompson, C. B., and Mak, T. W., Differential T cell costimulatory requirements in CD28-deficient mice, Science, 261, 609-612, 1993.
128. Kondo, M., Takeshita, T., Ishli, N., Nakamura, M., Watanab,e S., Arai, K., and Sugamura, K., Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4, Science, 262, 1874-1877, 1993.
129. Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., and Leonard, W. J., Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor, Science, 262, 1877-1880, 1993.
130. Russell, S. M., Keegan, A. D., Harada, N., Nakamura, Y., Noguchi, M., Leland, P., Friedmann, M. C., Miyajima, A., Puri, R. K., Paul, W. E., et al., Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor, Science, 262, 1880-1883, 1993.
131. Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D'Andrea, A. D., Ritz, J., and Nadler, L. M., Prevention of T cell energy by signaling through the gamma c chain of the IL-2 receptor, Science, 266, 1039-1042, 1994.
132. Quill, H., Riley, M. P., Cho, E. A., Casnellie, J. E., Reed, J. C., and Torigoe, T., Anergic Th1 cells express altered levels of the protein tyrosine kineses p561ck and pS9fyn, J. Immunol., 149, 2887-2893, 1992.
133. DeSilva, D. R., Urdahl, K. B., and Jenkins, M. K., Clonal energy is induced in vitro by T cell receptor occupancy in the absence of proliferation, J. Immunol., 147, 3261-3267, 1991.
134. Gilbert, K. M. and Weigle, W. O., Th1 cell energy and blockade in Gla phase of the cell cycle, J. Immunol., 151, 1245-1254, 1993.
135. Sloan-Lancaster, J., Evavold, B. D., and Alien, P. M., Induction of T-cell energy by altered T-cell-receptor ligand on live antigen-presenting cells, Nature, 363, 156-159, 1993.
136. Krummel, M. F. and Allison, J. P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J. Exp. Med., 182, 459-465, 1995.
137. Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B., and Abbas, A. K., Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement, Immunity, 6, 411-417, 1997.
138. Van Parijs, L., Perez, V. L., Binckians, A., Maki, R. G., London, C. A., and Abbas, A. K., Role of interleukin 12 and costimulators in T cell energy in vivo, J. Exp. Med., 186, 1119-1128, 1997.
139. Greenfield, E. A., Howard, E., Paradis, T., Nguyen, K., Benazzo, F., McLean, P., Höllsberg, P., Davis, G., Hafler, D. A., Sharpe, A. H., Freeman, G. J., and Kuchroo, V. K., B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors, J. Immunol., 158, 2025-2034, 1997.
140. Höllsberg, P., Scholz, C., Anderson, D. E., Greenfield, E. A., Kuchroo, V. K., Freeman, G. J., and Hafler, D. A., Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4, J. Immunol., 159, 4799-4805, 1997.
141. Guerder, S., Meyerhoff, J., and Flavell, R., The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen, Immunity, 1, 155-166, 1994.
142. Guerder, S., Picarella, D. E., Linsley, P. S., and Flavell, R. A., Costimulator B7-1 confers antigen-presenting cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice, Proc. Natl. Acad. Sci. U.S.A., 91, 5138-5142, 1994.
143. Harlan, D. M., Abe, R., Lee, K. P., and June, C. H., Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion, Clin. Immunol. Immunopathol., 75, 99-111, 1995.
144. Soldevila, G., Geiger, T., and Flavell, R. A., Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen, J. Immunol., 155, 5590-5600, 1995.
145. von Herrath, M. G., Guerder, S., Lewicki, H., Flavell, R. A., and Oldstone, M. B., Coexpression of B7-1 and viral (self) transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes, Immunity, 3, 727-738, 1995.
146. Wong, S., Guerder, S., Visintin, I., Reich, E. P., Swenson, K. E., Flavell, R. A., Janeway, C. A., Jr., Expression of the costimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse, Diabetes, 44, 326-329, 1995.
147. Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., and Bluestone, J. A., Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse, J. Exp. Med., 181, 1145-1155, 1995.
148. Verwilghen, J., Lovis, R., De Boer, M., Linsley, P. S., Haines, G. K., Koch, A. E., and Pope, R. M., Expression of functional B7 and CTLA4 on rheumatoid synovial T cells, J. Immunol., 153, 1378-1385, 1994.
149. Webb, L. M., Walmsley, M. J., and Feldmann, M., Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2, Eur. J. Immunol., 26, 2320-2328, 1996.
150. Sfikakis, P. P., Oglesby, R., Sfikakis, P., and Tsokos, G. C., B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE), Clin. Exp. Immunol., 96, 8-14, 1994.
151. Alvarado, C., Alcocer-Varela, J., Llorente, L., RichaudPatin, Y., Cerbon, M., and AlarconSegovia, D., Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus, J. Autoimmunol., 7, 763-773, 1994.
152. + T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis, Clin. Exp. Immunol., 106, 218-229, 1996.
153. Garcia-Cozar, F. J., Molina, I. J., Cuadrado, M. J., Marubayashi, M., Pena, J., and Santamaria, M., Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients, Clin. Exp. Immunol., 104, 72-79, 1996.
154. Nakajima, A., Azuma, M., Kodera, S., Nurlya, S., Terashi, A., Abe, M., Hirose, S., Shirai, T., Yagita, H., and Okumura, K., Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule, Eur. J. Immunol., 25, 3060-3069, 1995.
155. Zamvil, S. S. and Steinman, L., The T lymphocyte in experimental allergic encephalomyelitis, Annu. Rev. Immunol., 8, 579-621, 1990.
156. McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C., and Miller, S. D., Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis, J. Exp. Med., 182, 75-85, 1995.
157. Kumar, V., Kono, D. H., Urban, J. L., and Hood, L., The T-cell receptor repertoire and autoimmune diseases, Annu. Rev. Immunol., 7, 657-682, 1989.
158. De Simone, R., Giampnolo, A., Giometto, B., Gallo, P., Levi, G., Peschle, C., and Aloisi, F., The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions, J. Neuropathol. Exp. Neurol., 54, 175-187, 1995.
159. Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe, M. N., Cuzner, M. L., and Hafler, D. A., Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin-12 cytokine in multiple sclerosis lesions, J. Exp. Med., 182, 1985-1996, 1995.
160. Hurwitz, A. A., Sullivan, T. J., Krummel, M. F., Sobel, R. A., and Allison, J. P., Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis, J. Neuroimmunol., 73, 57-62, 1997.
161. Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., and Bluestone, J. A., CTLA-4: a negative regulator of autoimmune disease, J. Exp. Med., 184, 783-788, 1996.
162. Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H., and Racke, M. K., CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis, J. Immunol., 157; 1333-1336, 1996.
163. Arima, T., Rehman, A., Hickey, W.F., and Flye, M. W., Inhibition by CTLA4Ig of experimental allergic encephalmyelitis, J. Immunol., 156, 4916-4924, 1996.
164. Khoury, S. J., Akalin, E., Chandraker, A., Turka, L. A., Linsley, P. S., Sayegh, M. H. and Hancock, W. W., CD28-B7 costimulatory blockade by CTLA2Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system, J. Immunol., 155, 4521-4524, 1995.
165. Khoury, S. J., Gallon, L., Verburg, R. R., Chandraker, A., Peach, R., Linsley, P. S., Turka, L. A., Hancock, W. W., and Sayegh, M. H., Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat, J. Immunol., 157, 3700-3705, 1996.
166. Correale, J., McMillan, M., Li, S., McCarthy, K., Le, T., and Weiner, L. P., Antigen presentation by autoreactive proteolipid protein peptide-specific T cell clones from chronic progressive multiple sclerosis patients: roles of costimulatory B7 molecules and IL-12, J. Neuroimmunol., 72, 27-43, 1997.
167. Chou, Y. K., Bourdette, D. N., Offner, H., Whitham, R., Wang, R. Y., Hashim, G. A., and Vandenbark, A. A., Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis, J. Neuroimmunol., 38, 105-113, 1992.
168. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., Ikehara, S., et al., The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro, J. Exp. Med., 180, 1849-1860, 1994.
169. Larsen, C. P., Ritchie, S. C., Pearson, T. C, Linsley, P. S., and Lowry, R. P., Functional expression of the costimulatory molecule, B7/BB 1, on marine dendritic cell populations, J. Exp. Med., 176, 1215-1220, 1992.
170. Simon, J. C., Dietrich, A., Mielke, V., Wuttig, C., Vanscheidt, W., Linsley, P. S., Schopf, E., and Sterry, W., Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases, J. Invest. Dermatol., 103, 539-543, 1994.
171. Nickoloff, B. J., Nestle, F. O., Zheng, X. G., and Turka, L. A., T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B71: a ligand for CD28, Blood, 83, 2580-2586, 1994.
172. Townsend, A. and Bodmer, H., Antigen recognition by class I-restricted T lymphocytes, Annu. Rev. Immunol., 7, 601-624, 1989.
173. Tsomides, T. J. and Eisen, H. N., T-cell antigens in cancer, Proc. Natl. Acad. Sci. U.S.A., 91, 3487-3489, 1994.
174. Topalian, S. L., Solomon, D., and Rosenberg, S. A., Tumor-specific cytolysis by lymphocytes infiltrating human melanomas, J. Immunol., 142, 3714-3725, 1989.
175. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., toy, S, T. Simon, P., Lotze, M. T. Yang, J. C., Seipp, C. A., et al., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N. Engl. J. Med., 319, 1676-1680, 1988.
176. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A., Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol., 12, 337-365, 1994.
177. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S., Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell, 71, 1093-1102, 1992.
178. Chen, L., Linsley, P. S., and Hellstrom, K. E., Costimulation of T cells for tumor immunity, Immunol. Today, 14, 483-486, 1993.
179. Urban, J. L. and Schreiber, H., Tumor antigens, Annu. Rev. Immunol., 10, 617-644, 1992.
180. Elliott, B. E., Carlow, D. A., Rodricks, A. M., and Wade, A., Perspectives on the role of MHC antigens in normal and malignant cell development, Adv. Cancer Res., 53, 181-245, 1989.
181. + T cells by B7-transfected melanoma cells, Science, 259, 368-370, 1993.
182. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I., and Hellstrom, K. E., Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity, J. Exp. Med., 179, 523-532, 1994.
183. Fujii, H., Inobe, M., Kimura, F., Murata, J., Murakami, M., Onishi, Y., Azuma, I, Uede, T., and Saiki, I, Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the antimetastatic effect and tumor immunity in mice, Int. J. Cancer, 66, 219-224, 1996.
184. Hodge, J. W., Abrams, S., Schlom, J., and Kantor, J. A., Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules, Cancer Res., 54, 5552-5555, 1994.
185. La Motte, R. N., Rubin, M. A., Barr, E., Leiden, J. M., Bluestone, J. A., and Mokyr, M. B., Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule, Cancer Immunol. Immunother., 42, 161-169, 1996.
186. Yang, G., Hellstrom, K. E., Hellstrom, I., and Chen, L., Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/ CTLA-4 costimulatory molecules, J. Immunol., 154, 2794-2800, 1995.
187. Gajewski, T. F., Fallarino, F., Uyttenhove, C., and Boon, T., Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active turner immunization, J. Immunol., 156, 2909-2917, 1996.
188. Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, P., Nadler, L. M., and Griffin, J. D., B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct, J. Immunol., 156, 1126-1131, 1996.
189. Martin-Fontecha, A., Cavallo, F., Bellone, M., Heltai, S., Iezzi, G., Tornaghi, P., Nabavi, N., Forni, G., Dellabona, P., and Casorati, G., Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors, Eur. J. Immunol., 26, 1851-1859, 1996.
190. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., and Stern, P. L., Natural history of HLA expression during tumor development, Immunol. Today, 14, 491-499, 1993.
191. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., and Glimcher, L. H., Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules, Proc. Natl. Acad. Sci. U.S.A., 90, 5687-5690, 1993.
192. Heuer, J. G., Tucker-McClung, C., Gonin, R., and Hock, R. A., Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunoggenic neuroblastoma into a highly immunogenic one, Hum. Gene Ther., 7, 2059-2068, 1996.
193. Baskar, S., Clements, V. K., Glimcher, L. H., Nabavi, N., and Ostrand-Rosenberg, S., Rejection of MHC class II transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules, J. Immunol., 156, 3821-3827, 1996.
194. Bateman, W. J., Fiera, R., Matthews, N., and Morris, A. G., Inducibility of class II major histocompatibility complex antigens by Interferon gamma is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras, J. Exp. Med., 173, 193-196, 1991.
195. Borden, E. C. and Sondel, P. M., Lymphokines and cytokines as cancer treatment. Immunotherapy realized, Cancer, 65, 800-814, 1990.
196. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Tanlyama, T., and Sakata, T., Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity, Proc. Natl. Acad. Sci. U.S.A., 86, 9456-9460, 1989.
197. Coughlin, C. M., Wysocka, M., Kurzawa, H. L., Lee. W. M., Trinchieri, G., and Eck, S.L., B7-1 and interleukin 12 synergistically induce effective antitumor immunity, Cancer Res., 55, 4980-4987, 1995.
198. Ranheim, E. A. and Kipps, T. J., Activated T cells induce expression of B7/BB 1 on normal or leukemic B cells through a CD40-dependent signal, J. Exp. Med., 177, 925-935, 1993.
199. Upadhyaya, G., Cuba, S. C., Sih, S. A., Feinberg, A. P., Talpaz, M., Kantarjian, H. M., Deisseroth, A. B., and Emerson, S. G., Interferonalpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells, J. Clin. Invest., 88, 2131-2136, 1991.
200. Cavallo, F., Martln-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G., Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response, Eur. J. Immunol., 25, 1154-1162, 1995.
201. Bashuda, H., Seino, K., Kano, M., Sato, K., Azuma, M., Yagita, H., and Okomura, K., Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice, Transplant. Proc., 28, 1039-1041, 1996.
202. Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., and Tepper, M. A., Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule, Science, 257,792-795, 1992.
203. Lin, H., Bolling, S. F., Linsley, P. S., Wei, R. Q., Gordon, D., Thompson, C. B., and Turka, L. A., Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion, J. Exp. Med., 178, 1801-1806, 1993.
204. Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S., Gordon, D., et al., T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo, Proc. Natl. Acad. Sci. U.S.A., 89, 11102-11105, 1992.
205. Blazar, B. R., Widmer, M. B., Taylor, P. A., and Vallera, D. A., Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha, Blood, 80, 1614-1622, 1992.
206. Judge, T. A., Tang, A., Spain, L. M., Deans-Gratiot, J., Sayegh, M. H., and Turka, L. A., The in vivo mechanism of action of CTLA4Ig, J. Immunol., 156, 2294-2299, 1996.
207. Pirsch, J. D. and Maki, D. G., Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased suscepability to fungal infections, Ann. Intern. Med., 104, 619-631, 1986.
208. Schwarer, A. P., Jiang, Y. Z., Brookes, P. A., Barrett, A. J., Batchelor, J. R., Goldman, J. M., and Lechler, R. I., Frequency of antirecipient alloreactive helper T-cell precursors in donor blood and graft-vs.-host disease after HLA-identical sibling bone-marrow transplantation, Lancet, 341, 203-205, 1993.
209. Theobald, M., Nierle, T., Bunjes, D., Arnold, R., and Heimpel, H., Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-vs.-host disease in bone marrow transplantation between HLA-identical siblings, N. Engl. J. Med., 327, 1613-1617, 1992.
210. Hakim, F.T., Cepeda, R., Gray, G. S., June, C. H., and Abe, R., Acute graft-vs.-host reaction can be aborted by blockade of costimulatory molecules, J. Immunol., 155, 1757-1766, 1995.
211. Kirk, A. D., Harlan, D. M., Armstrong, N. N., Davis, T. A., Dong, Y., Gray, G. S., Hong, X., Thomas, D., Fechner, J. H., Jr., and Knechtle, S. J., CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates, Proc. Natl. Acad. Sci. U.S.A., 94, 8789-8794, 1997.
212. Kuiper, H. M., Brouwer, M., Linsley, P. S., and van Lier, R. A., Activated T cells can induce high levels of CTLA-4 expression on B cells, J. Immunol., 155, 1776-1783, 1995.
213. Leong, C., Marley, J., Loh, S., Robinson, B., and Garlepp, M., Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression, Cancer Gene. Ther., 3, 321-330, 1996.
214. Li, Y., Hellstrom, K. E., Newby, S. A., and Chen, L., Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors, J. Exp. Med., 183, 639-644, 1996.
215. Restifo, N. P., Esquivel, F., Asher, A. L., Stotter, H., Barth, R. J., Bennink, J. R., Mule, J. J., Yewdell, J. W., and Rosenberg, S. A., Defective presentation of endogenous antigens by a murine sarcoma, J. Immunol., 147, 1453-1459, 1991.
216. Wu, T. C., Huang, A. Y., Jaffee, E. M., Levitsky, H. I., and Pardoll, D. M., A reassessment of the role of B7-1 expression in tumor rejection, J. Exp. Med., 182, 1415-1421, 1995.
217. Grooten, J., Leroux-Roels, G., and Fiers, W., Specific suppression eleicited by EL4 lymphoma cells in syngeneic mice. Specificity includes self-antigens on EL4, Eur. J. Immunol., 17, 605-611, 1987.
218. Ramarathinam, L., Castle, M., Wu, Y., and Liu, Y., T cell costimulation by B7/BB1 induces CDS T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells, J. Exp. Med., 179, 1205-1214, 1994.
219. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G., Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response, Eur. J. Immunol., 25, 1154-1162, 1995.
220. Coughlin, C. M., Wysocka, M., Kurzawa, H. L., Lee, W. M., Trinchieri, G., and Eck, S. L., B7-1 and interleukin-12 synergistically induce effective tumor immunity, Cancer Res., 55, 4980-4987, 1995.
221. Mule, J. J., Yang, J. C., Afreniere, R. L., Shu, S., and Rosenberg, S. A., Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastasis by the systemic administration of high-dose recombinant interleukin2, J. Immunol., 139, 285-294, 1987.
222. Zitvogel, L., Robbing P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C. G., Tahara, H., Schreiber, R. D., and Lotze, M. T., Interleukin-12 and B7-1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors, Eur. J. Immunol., 26, 1335-1341, 1996.
223. Katsanis, E., Xu, Z., Bausero, M. A., Dancisak, B. B., Gorden, K. B., Davis, G., Gray, G. S., Orchard, P. J., and Blazar, B. R., B7-1 expression deceases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules, Cancer Gene. Ther., 2, 39-46, 1995.
224. Karre, K., Ljunggren, H. G., Piontek, G., and Kiessling, R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy, Nature, 319, 675-678, 1986.
225. Baskar, S., Nabavi, N., Glimcher, L. H., and Ostrand-Rosenberg, S., Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity, Immunother., 14, 209-215, 1993.
226. + melanoma, Int. Immunol., 12, 1501-1508, 1993.
227. + T cells specific for transporter associated with antigen processing deficient cells, Proc. Natl. Acad. Sci. U.S.A., 94,11496-11501, 1997.
228. Akalin, E., Chandraker, A., Russell, M. E., Turka, L. A., Hancock, W. W., and Sayegh, M. H., CD28-B7 T cell costimulatory blockade by CTLA4-Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo, Transplantation, 62, 1942-1945, 1996.
229. Azuma, H., Chandraker, A., Nadeau, K., Hancock, W. W., Carpenter, C. B., Tilney, N. L., and Sayegh, M. H., Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection, Proc. Natl. Acad. Sci. U.S.A., 93, 12439-12444, 1996.